Collaborations & Alliances

TYME Technologies, NYU Langone to Advance Metastatic Cancer Treatment

Aims to examine TYME’s metabolism-based cancer treatment, SM-88

Tyme Technologies, Inc. entered a new research collaboration with NYU Langone Health to advance the development of innovative treatments for patients with metastatic cancers, including pancreatic cancer.    The broad collaboration will examine the effects of TYME’s cancer metabolism-based therapy, SM-88, and each of the components of MPS (methoxsalen, phenytoin, and sirolimus) on primary pancreatic cancer cell lines, patient-derived pancreatic cancer organoids as well as specialized mouse xeno...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters